This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
The new horizons of advanced imaging, especially in oncology, must increasingly consider not only diagnostic efficacy but also sustainability for patients, prize-winning researchers told ECR 2025 delegates. To mitigate these effects, low-energy imaging techniques should be prioritized without compromising diagnostic accuracy.
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. An assistant professor of radiology and radiological science, Francis Deng, MD, is the Johns Hopkins radiology department's co-director of medical student diagnostic radiology electives.
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
reduction in average Medicare payment rates compared with 2024, the CMS has estimated there will be a 0% change to reimbursement for radiology, nuclear medicine, and radiation oncology. The American Society for Radiation Oncology (ASTRO) was disappointed in the final MPFS rule. Although the 2025 MPFS calls for an overall 2.9%
MIBI-SPECT/CT is considered the standard technique for guiding these surgeries, yet several phase II clinical trials suggest advantages of a newer approach using FCH-PET, such as superior spatial resolution for detecting small adenomas and lower radiation exposure to patients, they noted. The full study is available here.
The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. Preclinical studies demonstrated a high degree of radiation delivered to tumors while minimizing exposure to critical organs and tissues. It is not enough to develop a more powerful therapy.
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.
Central Vein Sign in Multiple Sclerosis: A Comparison Study of the Diagnostic Performance of 3T versus 7T MRI. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. Rankine, et al, International Journal of Radiation Oncology, Biology, Physics , September 1, 2023.
We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By
Ben Greenspan, MD, of VA Augusta (GA) Health, said he has never seen a patient harmed by a diagnostic extravasation or infiltration, and the claim that thousands of patients are being injured is "just not right. That might do away with diagnostic concerns, Flannery noted.
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. “PET Gauden , D.Phil.,
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.
produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies.
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics. Oncotarget. 2017 Jun 8;8(37):62742-62758.
The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. Be sure to visit us and experience our brand new 30′ x 30′ booth.
Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclear medicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.
We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Chief Executive Officer of Blue Earth Diagnostics. The findings were discussed in a poster Q&A session at the 2023 ASTRO Annual Meeting on October 3, 2023 ,“ Diagnostic Performance of 18 F-rhPSMA-7.3
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content